Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002315850 | SCV000674104 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2021-11-26 | criteria provided, single submitter | clinical testing | The p.I1688V variant (also known as c.5062A>G), located in coding exon 36 of the NF1 gene, results from an A to G substitution at nucleotide position 5062. The isoleucine at codon 1688 is replaced by valine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV001068057 | SCV001233146 | benign | Neurofibromatosis, type 1 | 2024-09-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001068057 | SCV002560510 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Gene |
RCV004787962 | SCV005401306 | uncertain significance | not provided | 2024-05-16 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |